|
1
|
Burger M, Catto J, Dalbagni GW, et al:
Epidemiology and risk factors of urothelial bladder cancer. Eur
Urol. 63:234–241. 2013. View Article : Google Scholar
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, et al: Cancer incidence and mortality patterns
in europe: estimates for 40 countries in 2012. Eur J Cancer.
49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumors. 7th edition.
Wiley-Blackwell; Hoboken, NJ, USA: pp. 262–265. 2009
|
|
4
|
Dalbagni G: Bladder cancer restaging TUR
reduces recurrence and progression risk. Nat Rev Urol. 7:649–650.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chan E, Patel A, Heston W and Larchian W:
Mouse orthotopic models for bladder cancer research. BJU Int.
104:1286–1291. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eiján AM, Lodillinsky C and Sandes EO:
Animal models for basic and preclinical research in bladder cancer.
Bladder Cancer - From Basic Science to Robotic Surgery. Canda AE:
InTech; pp. 383–404. 2012
|
|
7
|
Rubinsztein DC: How useful are animal
models of human disease? Semin Cell Dev Biol. 14:1–2. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Semsarian C: Use of mouse models for the
analysis of human disease. Curr Protoc Hum Genet. Chapter 15(Unit
15): 22002.
|
|
9
|
Williams PD, Lee JK and Theodorescu D:
Molecular credentialing of rodent bladder carcinogenesis models.
Neoplasia. 10:838–846. 2008.PubMed/NCBI
|
|
10
|
Steinberg GD, Brendler CB, Ichikawa T, et
al: Characterization of an N-methyl-N-nitrosourea-induced
autochthonous rat bladder cancer model. Cancer Res. 50:6668–6674.
1990.PubMed/NCBI
|
|
11
|
Babjuk M, Burger M, Zigeuner R, et al: EAU
guidelines on non-muscle-invasive urothelial carcinoma of the
bladder: update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reis LO, Pereira TC, Favaro WJ, et al:
Experimental animal model and RNA interference: a promising
association for bladder cancer research. World J Urol. 27:353–361.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Williams PD, Lee JK and Theodorescu D:
Molecular credentialing of rodent bladder carcinogenesis models.
Neoplasia. 10:838–846. 2008.PubMed/NCBI
|
|
14
|
Spry LA, Zenser TV, Cohen SM and Davis BB:
Role of renal metabolism and excretion in 5-nitrofuran-induced
uroepithelial cancer in the rat. J Clin Invest. 76:1025–1031. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cohen SM, Ohnishi T, Arnold LL and Le XC:
Arsenic-induced bladder cancer in an animal model. Toxicol Appl
Pharmacol. 222:258–263. 2007. View Article : Google Scholar
|
|
16
|
Sabichi A, Keyhani A, Tanaka N, et al:
Characterization of a panel of cell lines derived from urothelial
neoplasms: genetic alterations, growth in vivo and the relationship
of adenoviral mediated gene transfer to coxsackie adenovirus
receptor expression. J Urol. 175:1133–1137. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grossman HB, Wedemeyer G and Ren L:
UM-UC-1 and UM-UC-2: characterization of two new human transitional
cell carcinoma lines. J Urol. 132:834–837. 1984.PubMed/NCBI
|
|
18
|
Dobek GL and Godbey WT: An orthotopic
model of murine bladder cancer. J Vis Exp. 25352011.PubMed/NCBI
|
|
19
|
Yang XH, Ren LS, Wang GP, et al: A new
method of establishing orthotopic bladder transplantable tumor in
mice. Cancer Biol Med. 9:261–265. 2012.
|
|
20
|
Grivas PD, Day KC, Karatsinides A, et al:
Evaluation of the antitumor activity of dacomitinib in models of
human bladder cancer. Mol Med. 19:367–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shapiro A, Kelley DR, Oakley DM, et al:
Technical factors affecting the reproducibility of intravesical
mouse bladder tumor implantation during therapy with bacillus
calmette-guerin. Cancer Res. 44:3051–3054. 1984.PubMed/NCBI
|
|
22
|
Smith EB, Schwartz M, Kawamoto H, et al:
Antitumor effects of imidazoquinolines in urothelial cell carcinoma
of the bladder. J Urol. 177:2347–2351. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheon J, Moon DG, Cho HY, et al:
Adenovirus-mediated suicide-gene therapy in an orthotopic murine
bladder tumor model. Int J Urol. 9:261–267. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Horinaga M, Harsch KM, Fukuyama R, et al:
Intravesical interleukin-12 gene therapy in an orthotopic bladder
cancer model. Urology. 66:461–466. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang SG, Kim JI, Jung JC, et al:
Antimetastatic activity of the new platinum analog [Pt(cis-dach)
(DPPE). 2NO3] in a metastatic model of human bladder cancer.
Anticancer Res. 17:3239–3242. 1997.PubMed/NCBI
|
|
26
|
Jiang F and Zhou XM: A model of orthotopic
murine bladder (MBT-2) tumor implants. Urol Res. 25:179–182. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jager W, Moskalev I, Janssen C, et al:
Ultrasound-guided intramural inoculation of orthotopic bladder
cancer xenografts: a novel high-precision approach. PLoS One.
8:e595362013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Soloway MS and Masters S: Urothelial
susceptibility to tumor cell implantation: influence of
cauterization. Cancer. 46:1158–1163. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gunther JH, Jurczok A, Wulf T, et al:
Optimizing syngeneic orthotopic murine bladder cancer (MB49).
Cancer Res. 59:2834–2837. 1999.PubMed/NCBI
|
|
30
|
Mangsbo SM, Ninalga C, Essand M, et al:
CpG therapy is superior to BCG in an orthotopic bladder cancer
model and generates CD4+ T-cell immunity. J Immunother. 31:34–42.
2008. View Article : Google Scholar
|
|
31
|
Watanabe T, Shinohara N, Sazawa A, et al:
An improved intravesical model using human bladder cancer cell
lines to optimize gene and other therapies. Cancer Gene Ther.
7:1575–1580. 2000. View Article : Google Scholar
|
|
32
|
Yu DS, Lee CF and Chang SY: Immunotherapy
for orthotopic murine bladder cancer using bacillus calmette-guerin
recombinant protein Mpt-64. J Urol. 177:738–742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Knapp DW, Glickman NW, Denicola DB, et al:
Naturally-occurring canine transitional cell carcinoma of the
urinary bladder A relevant model of human invasive bladder cancer.
Urol Oncol. 5:47–59. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Knapp DW and Walters DJ: Naturally
occurring cancer in pet dogs: important models for developing
improved cancer therapy for humans. Mol Med Today. 3:8–11. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang T, Fan J, Wu K, et al: Roles of
HIF-1α in a novel optical orthotopic spontaneous metastatic bladder
cancer animal model. Urol Oncol. 30:928–935. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ayala DLPF, Kanasaki K, Kanasaki M, et al:
Loss of p53 and acquisition of angiogenic microRNA profile are
insufficient to facilitate progression of bladder urothelial
carcinoma in situ to invasive carcinoma. J Biol Chem.
286:20778–20787. 2011. View Article : Google Scholar
|
|
37
|
Wu XR: Biology of urothelial
tumorigenesis: insights from genetically engineered mice. Cancer
Metastasis Rev. 28:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ahmad I, Sansom OJ and Leung HY: Exploring
molecular genetics of bladder cancer: lessons learned from mouse
models. Dis Model Mech. 5:323–332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang ZT, Pak J, Shapiro E, et al:
Urothelium-specific expression of an oncogene in transgenic mice
induced the formation of carcinoma in situ and invasive
transitional cell carcinoma. Cancer Res. 59:3512–3517.
1999.PubMed/NCBI
|
|
40
|
Gollapudi BB, Stott WT, Yano BL and Bus
JS: Mode of action considerations in the use of transgenic animals
for mutagenicity and carcinogenicity evaluations. Toxicol Lett.
102–103:479–484. 1998. View Article : Google Scholar
|
|
41
|
He F, Mo L, Zheng XY, et al: Deficiency of
pRb family proteins and p53 in invasive urothelial tumorigenesis.
Cancer Res. 69:9413–9421. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kortylewski M, Xin H, Kujawski M, et al:
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the
tumor microenvironment. Cancer Cell. 15:114–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang L, Yi T, Kortylewski M, et al: IL-17
can promote tumor growth through an IL-6-Stat3 signaling pathway. J
Exp Med. 206:1457–1464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Langowski JL, Zhang X, Wu L, et al: IL-23
promotes tumour incidence and growth. Nature. 442:461–465. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Black PC and Dinney CP: Bladder cancer
angiogenesis and metastasis-translation from murine model to
clinical trial. Cancer Metastasis Rev. 26:623–634. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lodillinsky C, Rodriguez V, Vauthay L, et
al: Novel invasive orthotopic bladder cancer model with high
cathepsin B activity resembling human bladder cancer. J Urol.
182:749–755. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang Y, Revelo MP, Sudilovsky D, et al:
Development and characterization of efficient xenograft models for
benign and malignant human prostate tissue. Prostate. 64:149–159.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cutz JC, Guan J, Bayani J, et al:
Establishment in severe combined immunodeficiency mice of subrenal
capsule xenografts and transplantable tumor lines from a variety of
primary human lung cancers: potential models for studying tumor
progression-related changes. Clin Cancer Res. 12:4043–4054. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hofner T, Macher-Goeppinger S, Klein C, et
al: Development and characteristics of preclinical experimental
models for the research of rare neuroendocrine bladder cancer. J
Urol. 190:2263–2270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Growcott JW: Preclinical anticancer
activity of the specific endothelin a receptor antagonist ZD4054.
Anticancer Drugs. 20:83–88. 2009. View Article : Google Scholar
|
|
51
|
Wu Z, Owens C, Chandra N, et al: RalBP1 is
necessary for metastasis of human cancer cell lines. Neoplasia.
12:1003–1012. 2010.PubMed/NCBI
|
|
52
|
Bolenz C, Wenzel M, Cao Y, et al: Newly
developed mini-endoscope for diagnosis and follow-up of orthotopic
bladder transitional-cell carcinoma in vivo. J Endourol.
21:789–794. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Satoh H, Morimoto Y, Arai T, et al:
Intravesical ultrasonography for tumor staging in an orthotopically
implanted rat model of bladder cancer. J Urol. 177:1169–1173. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chan ES, Patel AR, Larchian WA and Heston
WD: In vivo targeted contrast enhanced micro-ultrasound to measure
intratumor perfusion and vascular endothelial growth factor
receptor 2 expression in a mouse orthotopic bladder cancer model. J
Urol. 185:2359–2365. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kikuchi E, Xu S, Ohori M, et al: Detection
and quantitative analysis of early stage orthotopic murine bladder
tumor using in vivo magnetic resonance imaging. J Urol.
170:1375–1378. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Johnson AM, Conover DL, Huang J, et al:
Early detection and measurement of urothelial tumors in mice.
Urology. 67:1309–1314. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
van der Horst G, van Asten JJ, Figdor A,
et al: Real-time cancer cell tracking by bioluminescence in a
preclinical model of human bladder cancer growth and metastasis.
Eur Urol. 60:337–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Han C, Gong Z, Hao L, et al: Mechanism of
monoclonal antibody-coupled staphylococcus superantigen-a induced
apoptosis in human bladder cancer cells. Cell Biochem Biophys.
61:679–684. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Amit D, Gofrit ON, Matouk I, et al: Use of
preclinical models to assess the therapeutic potential of new drug
candidates for bladder cancer. Semin Oncol. 39:534–542. 2012.
View Article : Google Scholar : PubMed/NCBI
|
